Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

LatviaBack to Latvia

Clinical trials in Riga – page 2

203 clinical trials in Riga, Latvia across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Riga at a glance
203
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

203 trials in Riga

Open in trial search

Bladder cancer

Recruiting

Long‑Term Follow‑Up of Mitomycin (UGN‑103) Treatment in Patients with Recurrent Low‑Grade Intermediate‑Risk Non‑Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Neovascular age-related macular degeneration

Recruiting

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Chronic obstructive pulmonary disease

Recruiting

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Age-related macular degeneration

Recruiting

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Generate Biomedicines Inc.

Small cell lung cancer

Recruiting

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Pulmonary arterial hypertension

Recruiting

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Pulmonary arterial hypertension

Recruiting

A study to evaluate the effectiveness and safety of REGN13335 in adults with pulmonary arterial hypertension

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B
  • Sponsor:Regeneron Pharmaceuticals Inc.

Interstitial lung disease+1

Recruiting

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Liquidia Technologies Inc.

Other cities in Latvia

The busiest research cities in the country

All 19 cities in Latvia

Clinical research in Riga

What the registry says about research in the country

01 Immunology & Vaccines

Research focusing on vaccine development and immune responses, including studies of combined vaccines for childhood diseases and immune system modulation in various conditions.

  • Measles-Mumps-Rubella-Varicella vaccine studies
  • Primary Immune Thrombocytopenia treatments
  • Novel immunotherapy approaches
02 Metabolic & Endocrine Disorders

Investigations into metabolic conditions and hormone-related disorders, with emphasis on treatment innovations and management strategies.

  • Glucagon response studies
  • Hypertriglyceridemia management
  • Post-menopausal osteoporosis treatment
03 Inflammatory Conditions

Clinical research targeting various inflammatory diseases, including dermatological and rheumatological conditions.

  • Psoriatic arthritis treatments
  • Plaque psoriasis therapies
  • Ulcerative colitis interventions
04 Oncology & Neurology

Studies focusing on innovative treatments for cancer and neurological disorders, including targeted therapies and combination approaches.

  • Non-small cell lung cancer treatments
  • Glioblastoma therapy
  • Dravet Syndrome management
05 Respiratory & Cardiovascular

Research into pulmonary conditions and heart-related disorders, exploring new therapeutic approaches.

  • Pulmonary arterial hypertension
  • Asthma treatment innovations
  • Heart failure interventions
Back to LatviaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.